Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Income towards Parent Company (2016 - 2025)

IGC Pharma has reported Income towards Parent Company over the past 16 years, most recently at -$1.8 million for Q3 2025.

  • Quarterly Income towards Parent Company fell 6.06% to -$1.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$6.4 million through Sep 2025, up 48.72% year-over-year, with the annual reading at -$7.1 million for FY2025, 45.22% up from the prior year.
  • Income towards Parent Company was -$1.8 million for Q3 2025 at IGC Pharma, down from -$1.6 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$1.2 million in Q1 2025 and troughed at -$6.5 million in Q1 2022.
  • The 5-year median for Income towards Parent Company is -$2.4 million (2021), against an average of -$2.8 million.
  • Year-over-year, Income towards Parent Company plummeted 162.16% in 2021 and then skyrocketed 67.28% in 2024.
  • A 5-year view of Income towards Parent Company shows it stood at -$2.4 million in 2021, then rose by 5.54% to -$2.2 million in 2022, then tumbled by 148.51% to -$5.6 million in 2023, then skyrocketed by 67.28% to -$1.8 million in 2024, then increased by 0.44% to -$1.8 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Income towards Parent Company are -$1.8 million (Q3 2025), -$1.6 million (Q2 2025), and -$1.2 million (Q1 2025).